Physician profile
John M Lee
NPI 1275849051
$17,803.30
in general payments reported to CMS, 2019-2025
55 companies · $2,809 in 2025
The $2,809 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,452 · 2020: $1,880 · 2021: $2,607 · 2022: $2,683 · 2023: $2,725 · 2024: $2,648 · 2025: $2,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,002 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,002.40 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,940.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,859.90 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,703.90 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,089.43 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,021.38 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $1,006.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $865.48 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $783.24 | 2019-2024 | |
| Abbott Laboratories | $746.88 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $736.13 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $718.76 | 2019-2025 | Xarelto, Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $602.13 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $472.99 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Dexcom, INC. | $433.02 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $428.05 | 2019-2025 | Otezla, Repatha, Evenity |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.